CN107495377A - 一种具有改善睡眠功能的保健食品及其制备方法 - Google Patents
一种具有改善睡眠功能的保健食品及其制备方法 Download PDFInfo
- Publication number
- CN107495377A CN107495377A CN201710949715.5A CN201710949715A CN107495377A CN 107495377 A CN107495377 A CN 107495377A CN 201710949715 A CN201710949715 A CN 201710949715A CN 107495377 A CN107495377 A CN 107495377A
- Authority
- CN
- China
- Prior art keywords
- sleep
- lily
- standby
- fruit
- poria cocos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 86
- 235000013402 health food Nutrition 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 41
- 241000234435 Lilium Species 0.000 claims abstract description 37
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 34
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 34
- 235000008434 ginseng Nutrition 0.000 claims abstract description 34
- 244000197580 Poria cocos Species 0.000 claims abstract description 32
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 32
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 32
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 30
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 30
- 229920002472 Starch Polymers 0.000 claims abstract description 23
- 235000019698 starch Nutrition 0.000 claims abstract description 23
- 239000008107 starch Substances 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 230000006872 improvement Effects 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 67
- 239000000284 extract Substances 0.000 claims description 51
- 241000208340 Araliaceae Species 0.000 claims description 34
- 239000000706 filtrate Substances 0.000 claims description 30
- 238000010992 reflux Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 12
- 238000004064 recycling Methods 0.000 claims description 12
- 241001065361 Gynostemma Species 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 206010013786 Dry skin Diseases 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000011122 softwood Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 235000013339 cereals Nutrition 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 5
- 230000001502 supplementing effect Effects 0.000 abstract description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 3
- 230000001147 anti-toxic effect Effects 0.000 abstract description 3
- 208000010643 digestive system disease Diseases 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract description 3
- 239000000932 sedative agent Substances 0.000 abstract description 3
- 230000001624 sedative effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000010411 cooking Methods 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 59
- 241000256856 Vespidae Species 0.000 description 40
- 238000012360 testing method Methods 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000000147 hypnotic effect Effects 0.000 description 12
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 11
- 229960000796 barbital sodium Drugs 0.000 description 11
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 11
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 206010022437 insomnia Diseases 0.000 description 10
- 230000028527 righting reflex Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000004620 sleep latency Effects 0.000 description 9
- 230000002567 autonomic effect Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000002035 prolonged effect Effects 0.000 description 8
- 230000004622 sleep time Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 235000014347 soups Nutrition 0.000 description 7
- 206010003084 Areflexia Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 206010039897 Sedation Diseases 0.000 description 5
- 230000001914 calming effect Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 230000036280 sedation Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 4
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 230000008925 spontaneous activity Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 3
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 3
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 3
- 235000008422 Schisandra chinensis Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 229930186669 gynosaponin Natural products 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- KKAHGGJBKUXDNQ-KRWDZBQOSA-N panaxynol Natural products CCCCCCCC=CC=CCC#C[C@@H](O)C=C KKAHGGJBKUXDNQ-KRWDZBQOSA-N 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010057315 Daydreaming Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 229960001301 amobarbital Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 230000000517 effect on sleep Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- -1 pachymaran Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229930192961 schisandrol Natural products 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 241000382825 Cristaria plicata Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241001669679 Eleotris Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 244000210789 Lilium lancifolium Species 0.000 description 1
- 241001359444 Lilium tenuifolium Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001212699 Pinctada martensii Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241001464055 Pteriidae Species 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000217379 Unionidae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940043200 pentothal Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- RXHIKAIVEMAPRU-JRIGQVHBSA-N sequiterpene Natural products C1=C(C)[C@@H](OC(C)=O)[C@H](O)[C@@]2(O)[C@H](C)CC[C@@H](C(C)=C)[C@H]21 RXHIKAIVEMAPRU-JRIGQVHBSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
- 239000008946 yang xin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有改善睡眠功能的保健食品,由茯苓420‑560、百合320‑460、绞股蓝300‑450、人参150‑250、五味子60‑160、珍珠粉8‑24、淀粉30‑120按重量份配比制成。本发明从中国数千年的饮食文化和中医传统理论出发,以中草药为原料,结合中西医理论,融益气养阴、宁心安神为一体,采用现代化加工工艺精制而成,既确保了中药的有效成分,又减少了服用量,具有改善睡眠的保健功能,且无毒副作用,适用于睡眠状况不佳者长期服用。本发明还公开了一种具有改善睡眠功能的保健食品的制备方法。
Description
技术领域
本发明属于保健食品技术领域,具体涉及一种具有改善睡眠功能的保健食品及其制备方法。
背景技术
人的一生当中,睡眠约占人们生命的三分之一,睡眠良好是身心健康的主要标志,是人类基本的生理需求。睡眠可以消除疲劳,恢复体力;保护大脑,恢复精力;增强免疫,康复机体;促进生长;延缓衰老;保护心理健康和皮肤美容。近年来,伴随着中国经济高速发展,生活成本逐步升高,社会竞争愈发激烈,人们所承受的来自生活、工作、学习等各方面的压力也越来越大,多数人长期处于精神高度紧张的状态。若这种状态得不到有效改善,就会影响到睡眠质量,严重时出现失眠。失眠主要表现为睡眠时间、深度的不足,轻者入睡困难,或寐而不酣,时寐时醒,或醒后不能再寐,重者彻夜不寐。失眠会影响体内各种激素的正常分泌,扰乱各种激素的分布水平,导致人体内分泌系统失调,影响人体的正常发育。经常失眠会导致注意力不集中、理解能力下降,学习效率降低,从而影响人的工作状态;长期失眠会使人体免疫力下降,抗病和康复疾病的能力低下,诱发原有疾病的发作,严重者诱发或加重心脑血管疾病、癌症、糖尿病、胃肠疾病等,甚至导致精神类疾病的产生,寿命减短。世界卫生组织已将失眠列为健康的首要威胁。因此,研制开发具有改善睡眠功能的保健食品是一项刻不容缓的工作。
发明内容
本发明的目的是提供了一种具有改善睡眠功能的保健食品。
本发明的另一个目的是提供一种具有改善睡眠功能的保健食品的制备方法。
本发明采用如下的技术方案:
一种具有改善睡眠功能的保健食品,由下列原料按重量份配比制成:
茯苓420-560 百合320-460 绞股蓝300-450 人参150-250
五味子60-160 珍珠粉8-24 淀粉30-120。
进一步的,优选的所述的保健食品由下列原料按重量份配比制成:
茯苓450-540 百合350-440 绞股蓝320-420 人参160-240
五味子80-150 珍珠粉10-20 淀粉50-100。
进一步的,优选的所述的保健食品由下列原料按重量份配比制成:
茯苓480-520 百合380-420 绞股蓝360-400 人参180-220
五味子100-140 珍珠粉12-18 淀粉60-90。
进一步的,优选的所述的保健食品由下列原料按重量份配比制成:
茯苓500 百合400 绞股蓝380 人参200
五味子120 珍珠粉15 淀粉70。
进一步的,所述的保健食品为胶囊形式。
一种如上所述具有改善睡眠功能的保健食品的制备方法,包括如下步骤:
1)茯苓、百合、绞股蓝、人参、五味子经净制,检验合格后,备用;
2)珍珠粉、淀粉经检验合格后,备用;
3)取绞股蓝、五味子用75%乙醇回流提取2-3次,每次加5-10倍量溶剂,各回流提取2-3小时,提取液滤过,药渣备用,合并滤液,滤液回收乙醇并浓缩至相对密度为1.30~1.35的浸膏,备用;
4)将人参分别用95%、70%、50%、30%乙醇回流提取1次,每次5-10倍量乙醇回流1.5-3小时,合并提取液,提取液用200目筛网滤过,合并滤液,药渣备用,滤液回收乙醇,并浓缩至相对密度为1.30~1.35的浸,备用;
5)茯苓、百合与上述醇提药渣加水煎煮2-3次,每次加5-10倍量水,各煎煮1.5-3小时,煎液滤过,合并滤液并减压浓缩至相对密度为1.30~1.35的浸膏,与上述两种浸膏合并,于65℃减压干燥,粉碎,过80目筛得干膏粉,备用;
6)将珍珠粉、淀粉混合均匀后,再与上述干膏粉混合均匀,用80%乙醇制软材,16目筛制粒,55~60℃干燥,14目筛整粒,装入0号胶囊,包装,检验,即得成品。
上述原料中,所述茯苓、百合、绞股蓝、人参、五味子、珍珠粉、淀粉均为市售原料。
本发明中,茯苓,为多孔菌科真菌茯苓的干燥菌核,味甘、淡,性平,归心、肺、脾、肾经,具有健脾、宁心的功效,用于心神不安,惊悸失眠等症。现代研究证明,茯苓含有茯苓酸、茯苓多糖、微量元素等多种化学成分和营养物质。实验结果表明,茯苓水煎液无直接睡眠作用,可明显增加戊巴比妥钠阈下剂量的动物入睡率,能明显延长阈上戊巴比妥钠小鼠睡眠时间。另有研究显示,茯苓水煎液可显著延长阈上剂量戊巴比妥钠引起小鼠睡眠时间;茯苓粗多糖能显著缩短小鼠的睡眠潜伏期,能显著增加小鼠睡眠时间。另研究结果表明,羧甲基茯苓多糖注射液具有催眠作用,能增强硫喷妥钠对小鼠中枢的抑制作用,使小鼠翻正反射消失持续的时间显著延长。采用茯苓水煎液治疗临床不寐24例1个月后,临床痊愈7例,显效9例,有效5例,总有效率87.5%。采用以茯苓等组成的养心汤加减治疗老年睡眠障碍52例3个月后,显效32例,有效15例,总有效率为90.38%。
百合,为百合科植物卷丹、百合或细叶百合的干燥肉质鳞叶,味甘,性寒,归心、肺经,具有养阴润肺,清心安神之功效,用于虚烦惊悸,失眠多梦,精神恍惚等症。百合具有“功有利于心肺,而能敛气养心,安神定魄”的作用。百合“安心,定胆,益志,养五脏。”百合中含有芬酸甘油酯、苷类、生物碱及多糖,还含一些磷脂、蛋白质和无机元素等营养物质。百合中所含的百合苷有镇静和催眠作用,实验证明,每晚睡眠前服用百合汤,有明显改善睡眠作用,可提高睡眠质量。实验表明百合能使小鼠的自发性活动计数明显减少,有一定的镇静作用。实验结果表明,高、中、低剂量的百合安眠汤均能明显减少小鼠自发活动次数,具有中枢镇静作用,高、中、低剂量的百合安眠汤均能增强戊巴比妥钠的作用,1.00g/kg的百合安眠汤可明显延长戊巴比妥钠的睡眠时间,且与10ml/kg安神补脑液效果相当,说明百合安眠汤具有较好的催眠作用。此外,给小鼠灌服百合水提液可明显延长戊巴比妥钠睡眠时间,并使阈下量戊巴比妥钠睡眠率显著提高。应用百合安神汤治疗顽固性失眠48例,结果治愈22例,有效19例,未愈7例,总有效率85.42%。
绞股蓝,为葫芦科植物绞股蓝的干燥全草,味苦,微甘,性寒,具有益气养阴,延缓衰老的功效,用于心悸气短,眩晕头疼,失眠等症。绞股蓝含有多种皂苷、三萜类、黄酮、甾醇、氨基酸、有机酸、无机盐、糖类、微量元素等化学成分。绞股蓝皂甙SH-6为人参二醇皂甙类,实验表明其明显抑制小白鼠的自主活动,增加戊巴比妥钠阈下剂量小白鼠的睡眠率和延长戊巴比妥钠睡眠剂量小白鼠的睡眠时间,说明它有明显的镇静、催眠作用。对绞股蓝总皂甙催眠作用进行了实验研究,结果高剂量组绞股蓝皂甙可以使小鼠自主活动明显减少(P<0.01);高剂量组与阈剂量戊巴比妥钠合用可以使小鼠睡眠时间延长(P<0.O1),高剂量组与阈下剂量戊巴比妥钠合用使小鼠入睡个数增加(P<0.01),说明绞股蓝皂甙具有催眠、镇静作用。研究发现,给药组与对照组小鼠分别腹腔注射绞股蓝水提取物和生理盐水,30min后每鼠腹腔注射60mg/kg戊巴比妥钠,以翻正反射消失为指标,记录小鼠睡眠时间,结果显示绞股蓝水提取物腹注100mg/kg或200mg/kg均能明显延长小鼠的戊巴比妥睡眠时间。从绞股蓝中提取了多糖配制成口服液治疗62例失眠患者,结果痊愈l8例,占29%,显效23例,占37.1%,有效15例,占24.2%,见效6例,占9.7%,总有效率为90.3%,表明本制剂具有益气养心,健脾和胃,宁神益智,镇静,催眠等功能,尤其对心脾两虚患者所引起的失眠症效果更佳。对由人参、绞股蓝等中药组成的还春宝口服液进行动物实验,结果还春宝口服液可延长戊巴比妥钠对小鼠的睡眠时间。
人参,为五加科植物人参的干燥根及根茎,味甘、微苦,性平,归脾、肺、心经,具有大补元气,补脾益肺,生津,安神的功效,用于惊悸失眠等症。人参的主要化学成分有人参皂甙、人参多糖、多肽、人参炔醇、麦芽酚及某些氨基酸和微量元素等。人参对中枢神经系统的作用,主要是使兴奋和抑制两种过程趋于平衡。人参皂甙Rb类有中枢镇静作用,Rb1、Rb2、Rc的混合物有安定作用。人参根皂苷50~200mg/kg使孤独饲养小鼠的睡眠时间随剂量增加而延长,200mg/kg组使8周隔离饲养小鼠20分钟内连续攻击时间有意义地下降,证明人参根皂苷具有中枢镇静作用。研究人参皂苷对电激痉挛所致小鼠神经失调改善作用的实验结果证明,电激痉挛后的小鼠给予人参根皂苷后,其自发运动量显著下降,由戊巴比妥钠诱导的睡眠时间明显延长。药理研究表明,人参炔醇对小鼠神经有阻断作用,对戊巴比妥钠阈下睡眠剂量的影响和对小鼠自发活动影响实验表明,人参炔醇有明显的镇静作用。运用人参养荣汤治疗失眠30例,治疗结果为治疗组30例,临床痊愈10例,显效7例,有效10例,无效3例,总有效率90.00%;对照组30例,临床痊愈7例,显效6例,有效9例,无效8例,总有效率73.33%,两组总有效率比较差异有非常显著性(P<0.05)。
五味子,为木兰科植物五味子的干燥成熟果实,味酸、甘,性温,归肺、心、肾经,具有益气生津、补肾宁心之功效,在中医临床上主要以单味或复方用于神经衰弱、心悸失眠等症。现代科学研究证明,五味子中含有挥发油、有机酸、维生素、木脂素、三萜、倍半萜及多糖等多种化学成分,其种仁乙醇提取物不但有中枢抑制作用,还有抗惊厥作用,且醇甲作用基本与之相似。研究五味子醇提取物对小鼠的镇静催眠作用,结果显示,与对照组相比较,五味子醇提取物能明显减少小鼠自主活动次数,增加阈下剂量戊巴比妥钠诱导小鼠的睡眠只数,缩短小鼠睡眠的潜伏期,说明五味子醇提取物具有显著的镇静催眠作用。给小鼠腹腔注射五味子醇甲能明显延长戊巴比妥钠及巴比妥钠的睡眠时间,减少小鼠自主活动,并加强利血平及戊巴比妥钠对自主活动的抑制作用,对抗咖啡因、苯丙胺对自主活动的兴奋作用。另有研究显示,五味子酒能够明显延长戊巴比妥钠诱导的小鼠睡眠时间,显著提高戊巴比妥钠诱导小鼠睡眠发生率,缩短巴比妥钠诱导小鼠睡眠潜伏期时间,对小鼠无直接催眠作用,对小鼠体重无明显影响,说明五味子酒具有改善睡眠效果的保健功能。研究结果表明,五味子水提物能明显减少小鼠自主活动次数,增加阈下睡眠剂量戊巴比妥钠致小鼠睡眠只数,延长阈上睡眠剂量戊巴比妥钠致小鼠睡眠时间,说明五味子具有明显的镇静、催眠作用。研究结果显示,五味子多糖能明显减少小鼠自主活动次数,增加阈下剂量戊巴比妥钠诱导小鼠睡眠只数,缩短小鼠睡眠潜伏期,显著延长阈剂量戊巴比妥钠诱导的小鼠睡眠时间,说明五味子多糖具有镇静、催眠的作用。研究表明,五味子宁神口服液能明显减少小鼠自主活动次数,增加阈下剂量戊巴比妥钠致小鼠睡眠只数,延长阈上剂量戊巴比妥钠致小鼠睡眠时间,延长小鼠发生惊厥的潜伏期及减少小鼠死亡只数,说明五味子宁神口服液有明显的镇静、催眠、抗惊厥作用。以五味子汤为主加味治疗68例失眠患者,治愈55例占80.88%,好转13例占19.12%,且均未出现任何毒副作用。
珍珠粉,为珍珠贝科动物马氏珍珠贝、或蚌科动物三角帆蚌、褶纹冠蚌等双壳类动物受刺激形成的珍珠,经粉碎而成的细粉,味甘、咸,性寒,入心、肝经,具有镇心安神,养阴熄风,清热坠痰,去翳明目,解毒生肌之效,主要用于惊悸,怔忡,癫痫,惊风搐搦等症。珍珠粉主要化学成分为碳酸钙、氨基酸、微量元素及蛋白质等。珍珠自古就有镇静催眠的作用,珍珠能“镇心定惊,清肝除翳,收敛生肌。”, “安魂魄,止遗精、白浊,解疽疔毒”。 现代药理研究表明,经口给予小鼠珍珠粉无直接睡眠作用,与溶剂对照组比较高剂量能明显的增加阈下剂量戊巴比妥钠小鼠入睡率,中和高剂量能显著缩短小鼠入睡时间,提示珍珠粉具有改善睡眠作用。研究显示,酶解珍珠口服液8、12ml/kg剂量组能明显延长阈剂量戊巴比妥钠诱导的小鼠睡眠时间,同时对阈下剂量戊巴比妥钠诱导小鼠睡眠发生率有明显升高,能明显缩短巴比妥钠诱导睡眠潜伏期,与对照组比较差异有显著性(P<0.05,P<0.01)。现代药理研究表明,腹腔注射珍珠粉混悬液可使家兔皮层电活动呈抑制性波型,并可延长咖啡因引起的惊厥潜伏时间,及腹腔注射珍珠粉混悬液可使小鼠脑内5-HT及 5-HIAA 水平明显升高,NA水平有所下降表明珍珠粉对中枢神经系统有一定程度的抑制作用。另有试验表明,70味珍珠丸可明显减少小鼠的自发活动,对戊巴比妥钠闭下睡眠剂量有明显的协同作用,还可显著增强乙醚前睡眠作用,提示该药具有明显的中枢镇静作用。对由珍珠粉等组成安梦胶囊进行了功能性评价试验,结果显示安梦胶囊与对照组比较小鼠的入睡数与入睡率均高于对照组,并能显著延长小鼠睡眠时间。
综上所述,本发明产品从中国数千年的饮食文化和中医传统理论出发,以中草药为原料,结合中西医理论,融益气养阴、宁心安神为一体,研制开发出了保健食品,方中茯苓健脾、宁心;百合养阴润肺,清心安神;绞股蓝益气养阴;人参大补元气,补脾益肺,生津,安神;五味子益气生津、补肾宁心;珍珠粉安神定惊,诸药配伍,共奏益气养阴,宁心安神之功效,从而达到改善睡眠状况不佳人群生活质量的目的。本品选用茯苓、百合、绞股蓝、人参、五味子、珍珠粉、淀粉为原辅料,采用现代化加工工艺精制而成,既确保了中药的有效成分,又减少了服用量,具有改善睡眠的保健功能,且无毒副作用,适用于睡眠状况不佳者长期服用。
附图说明
图1为本发明制备方法的流程图。
具体实施方式
下面结合实施例对本发明进一步详细说明。但本领域技术人员了解,下述实施例不是对本发明保护范围的限制,任何在本发明基础上做出的改进和变化,都在本发明的保护范围之内。
实施例1
1)茯苓540重量份、百合440重量份、绞股蓝420重量份、人参240重量份、五味子150重量份,经净制,检验合格后供制剂使用。
2)珍珠粉20重量份、淀粉100重量份,经检验合格后供制剂使用。
3)取绞股蓝420重量份、五味子150重量份,用75%乙醇回流提取3次,每次加8倍量溶剂,各回流提取2小时,提取液滤过(药渣另器存放备用),合并滤液,滤液回收乙醇(-0.065~-0.075Mpa,65℃)并浓缩至相对密度为1.30~1.35(60℃)的浸膏Ⅰ,备用。
4)将人参240重量份,分别用95%、70%、50%、30%乙醇回流提取1次,每次8倍量乙醇回流2小时,合并提取液,提取液用200目筛网滤过,合并滤液(药渣备用),滤液回收乙醇(-0.065~-0.075Mpa,65℃),并浓缩至相对密度为1.30~1.35(60℃测)的浸膏Ⅱ,备用。
5)茯苓540重量份、百合440重量份与醇提药渣加水煎煮3次,每次加6倍量水,各煎煮1.5小时,煎液滤过,合并滤液并减压浓缩(-0.065~-0.075Mpa,75℃)至相对密度为1.30~1.35(60℃)的浸膏Ⅲ,与上述浸膏Ⅰ、浸膏Ⅱ合并,于65℃减压(-0.085Mpa)干燥,粉碎,过80目筛,备用。
6)将珍珠粉20重量份、淀粉100重量份混合均匀后,再与上述干膏粉混合均匀,用80%乙醇制软材,16目筛制粒,55~60℃干燥,14目筛整粒,装入0号胶囊,包装,检验,即得成品。
实施例2
1)茯苓450重量份、百合350重量份、绞股蓝320重量份、人参160重量份、五味子80重量份,经净制,检验合格后供制剂使用。
2)珍珠粉10重量份、淀粉50重量份,经检验合格后供制剂使用。
3)取绞股蓝320重量份、五味子80重量份,用75%乙醇回流提取2次,每次加9倍量溶剂,各回流提取3小时,提取液滤过(药渣另器存放),合并滤液,滤液回收乙醇(-0.065~-0.075Mpa,65℃)并浓缩至相对密度为1.30~1.35(60℃)的浸膏Ⅰ,备用。
4)将人参240重量份,分别用95%、70%、50%、30%乙醇回流提取1次,每次9倍量乙醇回流3小时,合并提取液,提取液用200目筛网滤过,合并滤液(药渣备用),滤液回收乙醇(-0.065~-0.075Mpa,65℃),并浓缩至相对密度为1.30~1.35(60℃测)的浸膏Ⅱ,备用。
5)茯苓450重量份、百合350重量份与醇提药渣加水煎煮2次,每次加10倍量水,各煎煮1.5小时,煎液滤过,合并滤液并减压浓缩(-0.065~-0.075Mpa,75℃)至相对密度为1.30~1.35(60℃)的浸膏Ⅲ,与上述浸膏Ⅰ、浸膏Ⅱ合并,于65℃减压(-0.085Mpa)干燥,粉碎,过80目筛,备用。
6)将珍珠粉10重量份、淀粉50重量份混合均匀后,再与上述干膏粉混合均匀,用80%乙醇制软材,16目筛制粒,55~60℃干燥,14目筛整粒,装入0号胶囊,包装,检验,即得成品。
实施例3
1)茯苓480重量份、百合400重量份、绞股蓝350重量份、人参180重量份、五味子100重量份,经净制,检验合格后供制剂使用。
2)珍珠粉18重量份、淀粉80重量份,经检验合格后供制剂使用。
3)取绞股蓝350重量份、五味子100重量份,用75%乙醇回流提取2次,每次加6倍量溶剂,各回流提取3小时,提取液滤过(药渣另器存放),合并滤液,滤液回收乙醇(-0.065~-0.075Mpa,65℃)并浓缩至相对密度为1.30~1.35(60℃)的浸膏Ⅰ,备用。
4)将人参180重量份,分别用95%、70%、50%、30%乙醇回流提取1次,每次7倍量乙醇回流3小时,合并提取液,提取液用200目筛网滤过,合并滤液(药渣备用),滤液回收乙醇(-0.065~-0.075Mpa,65℃),并浓缩至相对密度为1.30~1.35(60℃测)的浸膏Ⅱ,备用。
5)茯苓480重量份、百合400重量份与醇提药渣加水煎煮3次,每次加5倍量水,各煎煮3小时,煎液滤过,合并滤液并减压浓缩(-0.065~-0.075Mpa,75℃)至相对密度为1.30~1.35(60℃)的浸膏Ⅲ,与上述浸膏Ⅰ、浸膏Ⅱ合并,于65℃减压(-0.085Mpa)干燥,粉碎,过80目筛,备用。
6)将珍珠粉18重量份、淀粉80重量份混合均匀后,再与上述干膏粉混合均匀,用80%乙醇制软材,16目筛制粒,55~60℃干燥,14目筛整粒,装入0号胶囊,包装,检验,即得成品。
实施例4
1)茯苓500重量份、百合400重量份、绞股蓝380重量份、人参200重量份、五味子120重量份,经净制,检验合格后供制剂使用。
2)珍珠粉15重量份、淀粉70重量份,经检验合格后供制剂使用。
3)取绞股蓝380重量份、五味子120重量份,用75%乙醇回流提取2次,每次加8倍量溶剂,各回流提取2小时,提取液滤过(药渣另器存放),合并滤液,滤液回收乙醇(-0.065~-0.075Mpa,65℃)并浓缩至相对密度为1.30~1.35(60℃)的浸膏Ⅰ,备用。
4)将人参200重量份,分别用95%、70%、50%、30%乙醇回流提取1次,每次8倍量乙醇回流1.5小时,合并提取液,提取液用200目筛网滤过,合并滤液(药渣备用),滤液回收乙醇(-0.065~-0.075Mpa,65℃),并浓缩至相对密度为1.30~1.35(60℃测)的浸膏Ⅱ,备用。
5)茯苓500重量份、百合400重量份与醇提药渣加水煎煮2次,每次加9倍量水,各煎煮1.5小时,煎液滤过,合并滤液并减压浓缩(-0.065~-0.075Mpa,75℃)至相对密度为1.30~1.35(60℃)的浸膏Ⅲ,与上述浸膏Ⅰ、浸膏Ⅱ合并,于65℃减压(-0.085Mpa)干燥,粉碎,过80目筛,备用。
6)将珍珠粉15重量份、淀粉70重量份混合均匀后,再与上述干膏粉混合均匀,用80%乙醇制软材,16目筛制粒,55~60℃干燥,14目筛整粒,水分≤5%,装入0号胶囊,包装,检验,即得成品。
试验例:
以下通过试验例来进一步阐述本发明胶囊的有益效果,这些试验例包括三个实验组,每个实验组包括阴性对照组(蒸馏水)、低、中、高剂量组。实验一组进行直接睡眠实验和延长戊巴比妥钠睡眠时间实验,实验二组进行戊巴比妥钠阈下剂量催眠实验,实验三组进行巴比妥钠睡眠潜伏期实验。
该胶囊人群推荐日摄入量2.4g/60kgBW(即0.04g/kgBW),扩大10、20、30倍,设置低、中、高三个剂量组,各组实验动物数(SPF级昆明种雌性小鼠,18-20g,144只)均为12只。
试验例1:受试样品对直接睡眠实验和延长戊巴比妥钠诱导睡眠时间实验结果的影响
直接睡眠实验
方法:观察动物给予受试物后是否出现睡眠现象,睡眠以翻正反射消失为指标。当小鼠置于背卧位时,能立即翻正身位。如超过30-60秒不能翻正者,即认为翻正反射消失,进入睡眠。翻正反射恢复即为动物觉醒,翻正反射消失至恢复这段时间为动物睡眠时间,记录各组入睡动物数及睡眠时间。根据实验动物使用3R原则,实验一组动物继续进行“延长戊巴比妥钠睡眠时间试验”。
延长戊巴比妥钠诱导小鼠睡眠时间实验
方法:末次给予受试物15min后,各组动物按50mg/kg BW剂量腹腔注射戊巴比妥钠(戊巴比妥钠临用前用生理盐水配制,其浓度为0.50%),注射量为10ml/kg BW,以小鼠翻正反射消失达1min以上为睡眠指标,观察受试物对戊巴比妥钠睡眠时间的延长作用。
试验结果:
给予受试样品后各剂量组小鼠活动正常,直接睡眠实验中,未出现小鼠翻正反射消失的现象,未观察到受试样品有直接睡眠作用,见表1。
表1 受试样品对小鼠直接睡眠的影响
受试样品高剂量组能显著延长戊巴比妥钠诱导小鼠睡眠时间,与阴性对照组比较,有显著性差异(P<0.05),件表2。
表2 受试样品对延长戊巴比妥钠诱导小鼠睡眠时间的影响(均数±标准差)
试验例2:受试样品对戊巴比妥钠阈下剂量催眠实验结果的影响
方法:末次给予受试物15min后,各组动物按30mg/kg BW剂量腹腔注射戊巴比妥钠(戊巴比妥钠临用前用生理盐水配制,其浓度为0.30%),注射量为10ml/kg BW,以小鼠翻正反射消失达1min以上为入睡判断标准,观察给戊巴比妥钠30min内各组动物睡眠发生率。
试验结果:
受试样品高剂量组能显著提高阈下剂量戊巴比妥钠诱导的小鼠睡眠发生率,与阴性对照组比较,有显著性差异(P<0.05),见表3。
表3 受试样品对戊巴比妥钠阈下剂量诱导小鼠睡眠发生率的影响
试验例3:受试样品对巴比妥钠睡眠潜伏期实验结果的影响
方法:末次给予受试物15min后,各组动物按250mg/kg BW剂量腹腔注射巴比妥钠(巴比妥钠临用前用生理盐水配制,其浓度为2.50%),注射量为10ml/kg BW,以小鼠翻正反射消失达1min以上为入睡判断标准,观察受试物对巴比妥钠睡眠潜伏期的影响。
试验结果:
受试样品各剂量组均未有明显缩短小鼠巴比妥钠睡眠潜伏期作用,与阴性对照组比较,均无显著性差异(均P>0.05),见表4。
表4 受试样品对巴比妥钠睡眠潜伏期的影响(均数±标准差)
结论:1)各剂量组均无明显直接睡眠作用;2)高剂量组能显著延长戊巴比妥钠诱导小鼠睡眠时间;3)高剂量组能显著提高阈下剂量戊巴比妥钠诱导的小鼠睡眠发生率;4)各剂量组均未有明显缩短小鼠巴比妥钠睡眠潜伏期作用。
延长戊巴比妥钠睡眠时间实验、戊巴比妥钠(或巴比妥钠)阈下剂量催眠实验、巴比妥钠睡眠潜伏期实验三项实验中任两项阳性,且无明显直接睡眠作用,可判定该受试样品具有改善睡眠功能的作用。
Claims (6)
1.一种具有改善睡眠功能的保健食品,由下列原料按重量份配比制成:
茯苓420-560 百合320-460 绞股蓝300-450 人参150-250
五味子60-160 珍珠粉8-24 淀粉30-120。
2.根据权利要求1所述的一种具有改善睡眠功能的保健食品,其特征在于所述的保健食品由下列原料按重量份配比制成:
茯苓450-540 百合350-440 绞股蓝320-420 人参160-240
五味子80-150 珍珠粉10-20 淀粉50-100。
3.根据权利要求1所述的一种具有改善睡眠功能的保健食品,其特征在于所述的保健食品由下列原料按重量份配比制成:
茯苓480-520 百合380-420 绞股蓝360-400 人参180-220
五味子100-140 珍珠粉12-18 淀粉60-90。
4.根据权利要求1所述的一种具有改善睡眠功能的保健食品,其特征在于所述的保健食品由下列原料按重量份配比制成:
茯苓500 百合400 绞股蓝380 人参200
五味子120 珍珠粉15 淀粉70。
5.根据权利要求1所述的一种具有改善睡眠功能的保健食品,其特征在于所述的保健食品为胶囊形式。
6.根据权利要求1所述的一种具有改善睡眠功能的保健食品的制备方法,包括如下步骤:
1)茯苓、百合、绞股蓝、人参、五味子经净制,检验合格后,备用;
2)珍珠粉、淀粉经检验合格后,备用;
3)取绞股蓝、五味子用75%乙醇回流提取2-3次,每次加5-10倍量溶剂,各回流提取2-3小时,提取液滤过,药渣备用,合并滤液,滤液回收乙醇并浓缩至相对密度为1.30~1.35的浸膏,备用;
4)将人参分别用95%、70%、50%、30%乙醇回流提取1次,每次5-10倍量乙醇回流1.5-3小时,合并提取液,提取液用200目筛网滤过,合并滤液,药渣备用,滤液回收乙醇,并浓缩至相对密度为1.30~1.35的浸,备用;
5)茯苓、百合与上述醇提药渣加水煎煮2-3次,每次加5-10倍量水,各煎煮1.5-3小时,煎液滤过,合并滤液并减压浓缩至相对密度为1.30~1.35的浸膏,与上述两种浸膏合并,于65℃减压干燥,粉碎,过80目筛得干膏粉,备用;
6)将珍珠粉、淀粉混合均匀后,再与上述干膏粉混合均匀,用80%乙醇制软材,16目筛制粒,55~60℃干燥,14目筛整粒,装入0号胶囊,包装,检验,即得成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710949715.5A CN107495377A (zh) | 2017-10-13 | 2017-10-13 | 一种具有改善睡眠功能的保健食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710949715.5A CN107495377A (zh) | 2017-10-13 | 2017-10-13 | 一种具有改善睡眠功能的保健食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107495377A true CN107495377A (zh) | 2017-12-22 |
Family
ID=60701239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710949715.5A Pending CN107495377A (zh) | 2017-10-13 | 2017-10-13 | 一种具有改善睡眠功能的保健食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107495377A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113750221A (zh) * | 2020-06-03 | 2021-12-07 | 上海培勇生物科技有限公司 | 一种改善睡眠的组合物及其制备方法 |
CN113826896A (zh) * | 2021-09-23 | 2021-12-24 | 营养屋(成都)生物医药有限公司 | 一种改善睡眠的保健食品及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1830314A (zh) * | 2006-03-31 | 2006-09-13 | 杨长辉 | 一种抗氧化和改善睡眠的保健食品 |
CN102940768A (zh) * | 2012-09-03 | 2013-02-27 | 吉林一正药业集团有限公司 | 一种改善睡眠的组合物及其制备方法和应用 |
-
2017
- 2017-10-13 CN CN201710949715.5A patent/CN107495377A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1830314A (zh) * | 2006-03-31 | 2006-09-13 | 杨长辉 | 一种抗氧化和改善睡眠的保健食品 |
CN102940768A (zh) * | 2012-09-03 | 2013-02-27 | 吉林一正药业集团有限公司 | 一种改善睡眠的组合物及其制备方法和应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113750221A (zh) * | 2020-06-03 | 2021-12-07 | 上海培勇生物科技有限公司 | 一种改善睡眠的组合物及其制备方法 |
CN113826896A (zh) * | 2021-09-23 | 2021-12-24 | 营养屋(成都)生物医药有限公司 | 一种改善睡眠的保健食品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104998098B (zh) | 一种改善睡眠的固体饮料及制备方法 | |
CN105725211A (zh) | 一种用于改善睡眠的食品保健品及其制备方法 | |
CN104873745B (zh) | 一种治疗失眠的中药及制备方法 | |
KR20100106976A (ko) | 우울증 및 불안 치료용 약학적 조성물 | |
CN110585331A (zh) | 一种桑葚助眠膏及制备方法 | |
CN102526217B (zh) | 一种增强免疫力、促进睡眠功能保健药物 | |
CN108567889A (zh) | 一种有效调控睡眠因子的中药组合物及其制备方法与应用 | |
CN1408397A (zh) | 含褪黑素和益智中药的组合物 | |
CN104323153A (zh) | 降三高保健食品 | |
CN105250913B (zh) | 一种治疗蛋鸡脂肪肝综合症的药物组合物 | |
CN107495377A (zh) | 一种具有改善睡眠功能的保健食品及其制备方法 | |
CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
CN1471845A (zh) | 一种以灵芝、天麻为原料的保健食品及其制备方法 | |
CN112843174A (zh) | 一种具有补脾养心安神功能的中药组合物及制备方法以及应用 | |
CN107412439A (zh) | 辅助调节更年期症状并抗癌防癌的人参组合物及制备方法 | |
CN104225295B (zh) | 用于改善睡眠的组合物及其制备方法和应用 | |
CN101904501B (zh) | 一种缓解疲劳的功能食品及其制备方法 | |
CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
CN100409878C (zh) | 一种抗衰老药物及其制备方法 | |
CN108126160A (zh) | 中药组合物与中药养生茶及其制备方法与用途 | |
CN108420799A (zh) | 促眠解压药食同源压片及其制备方法 | |
CN104435298B (zh) | 一种抗抑郁药物组合物 | |
CN112402569A (zh) | 一种抗疲劳保健品及其制备方法 | |
CN106361976A (zh) | 一种安神助眠养颜复方制剂及其制备方法 | |
CN103525640A (zh) | 一种活力壮阳酒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171222 |